Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944396 · ClinicalTrials.gov registry record · Phase 1
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02944396 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 25 participants.
The verdict
NCT02944396, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess whether the addition of nivolumab to veliparib in combination with platinum doublet chemotherapy results will improve progression free survival (PFS) compared to veliparib with platinum doublet chemotherapy alone in participants with metastatic or advanced Non-small Cell Lung Cancer (NSCLC) (Phase 2 portion). A strategy decision was made not to proceed to Phase 2 portion of this study due to change in standard of care.
Interventions
- DRUG carboplatin
- DRUG nivolumab
- DRUG pemetrexed
- DRUG paclitaxel
- DRUG veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-12-23 |
| Est. Completion | 2019-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944396
The ClinicalTrials.gov registry entry for NCT02944396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT02944396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02944396 about?
NCT02944396 is a clinical study titled "Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)". This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess whether the addition of nivolumab to veliparib in combination with platinu...
What is the current status of trial NCT02944396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-12-23. Estimated completion is 2019-10-02.
What interventions are being tested in trial NCT02944396?
The interventions under investigation include: carboplatin (DRUG), nivolumab (DRUG), pemetrexed (DRUG), paclitaxel (DRUG), veliparib (DRUG).
Who is sponsoring clinical trial NCT02944396?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.